| Literature DB >> 23773482 |
Stephen N Carmichael, James E Bron, John B Taggart, Jacqueline H Ireland, Michaël Bekaert, Stewart Tg Burgess, Philip J Skuce, Alasdair J Nisbet, Karim Gharbi, Armin Sturm.
Abstract
BACKGROUND: Caligid copepods, also called sea lice, are fish ectoparasites, some species of which cause significant problems in the mariculture of salmon, where the annual cost of infection is in excess of €300 million globally. At present, caligid control on farms is mainly achieved using medicinal treatments. However, the continued use of a restricted number of medicine actives potentially favours the development of drug resistance. Here, we report transcriptional changes in a laboratory strain of the caligid Lepeophtheirus salmonis (Krøyer, 1837) that is moderately (~7-fold) resistant to the avermectin compound emamectin benzoate (EMB), a component of the anti-salmon louse agent SLICE® (Merck Animal Health).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23773482 PMCID: PMC3691771 DOI: 10.1186/1471-2164-14-408
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Susceptibility of salmon louse laboratory strains to emamectin benzoate (EMB). Toxicity responses of adult male salmon lice (Lepeophtheirus salmonis) laboratory strains S and PT in 24 hours immotility bioassays. Symbols represent the immotility response observed in one of duplicate beakers of ten individuals included for each combination of strain and treatment. Dose–response relationships (solid lines) were established using probit analysis, and yielded EC50 values of 73.9 μg L-1 (95% confidence intervals: 58.9 - 92.0 μg L-1) for the S strain and 642.3 μg L-1 (642.3 - 957.4 μg L-1) for the PT strain.
Figure 2Design of microarray experiments. Microarray analysis was used to measure transcriptomic profiles in drug-susceptible (S) or EMB resistant (PT) salmon louse strains. In experiment 1, adult male salmon lice were collected for RNA extraction directly after removal from host fish. In experiment 2, salmon lice were removed from hosts and then subjected to exposure of seawater containing 200 μg L-1 of EMB for 1 or 3 hours before sampling. Control treatments included exposures to seawater, or seawater containing the solvent PEG300, which was used to solubilise EMB. The number of pools of four salmon lice sampled for each combination of treatment and strain is given as n.
Composition of features on custom oligo microarrays
| Annotated | 13, 542 | 10,056 |
| Unannotated | 1,566* | 5,052* |
| Control probes | 100 | 100 |
| Agilent controls | 536 | 536 |
| Total | 15744 | 15744 |
* Oligo probes were designed to both the forward and reverse complement sequence for all targets that were not suitably annotated but included on the custom microarrays.
Figure 3Comparison of microarray features differentially expressed across salmon louse strains between experiments. Genes differentially expressed between two salmon lice strains differing in EMB susceptibility (S, PT) were determined by microarray analysis in two independent experiments. Features that showed differential expression between strains (fold change ≥ 1.3, p < 0.05) were derived for both experiments. The Venn diagram only includes features studied in both experiments. *A total of 226 genes showed comparable differential expression between salmon louse strains in two independent microarray experiments and were therefore selected for further analysis of biological function.
Genes showing differential expression between salmon louse strains differing in EMB susceptibility
| | | | | ||
| ADD24187.1 | Neuronal acetylcholine receptor subunit alpha-3 | -3.21 | 7.59E-05 | -2.52 | 4.29E-03 |
| | | | | ||
| ACO15001.1 | Cytochrome P450 3A24 | -1.48 | 1.95E-03 | -1.31 | 4.13E-02 |
| | | | | ||
| ADD24462.1 | Cerebellin-3 | -1.86 | 3.60E-04 | -4.91 | 3.53E-06 |
| | | | | ||
| ADD38111.1 | Beta-crystallin A1 | 2.33 | 6.79E-05 | 1.37 | 1.35E-02 |
| | | | | ||
| NP_001116712.1 | Solute carrier family 8 (sodium/calcium exchanger) | -2.10 | 3.63E-04 | -4.38 | 1.74E-05 |
| EFX88361.1 | Alpha subunit of Na+/K+ ATPase | -1.67 | 2.21E-04 | -2.08 | 5.34E-05 |
| ACO12613.1 | Excitatory amino acid transporter 3 | -1.42 | 1.10E-04 | -1.34 | 4.96E-02 |
| | | | | ||
| ADD38332.1 | Troponin I | -1.77 | 4.85E-05 | -2.61 | 1.17E-06 |
| XP_001950563.1 | Muscle LIM protein | -1.67 | 1.57E-04 | -2.30 | 1.32E-06 |
| AAA17371.1 | Fast myosin heavy chain | -2.11 | 1.73E-03 | -6.23 | 1.68E-06 |
| ACO13186.1 | Myosin light chain alkali | -2.65 | 1.69E-05 | -3.38 | 8.46E-06 |
| ACO12924.1 | Myosin light chain alkali | -2.06 | 1.16E-05 | -3.69 | 9.66E-06 |
| ABU41018.1 | Collagen alpha-1 chain | -1.38 | 1.51E-03 | -6.85 | 2.61E-05 |
| EFV61840.1 | Smoothelin | -1.43 | 4.03E-04 | -1.85 | 6.25E-05 |
| ACO12887.1 | Troponin T | -1.73 | 1.04E-03 | -2.93 | 8.12E-05 |
| ADV40202.1 | Troponin 1 | -1.94 | 1.87E-03 | -2.93 | 3.23E-04 |
| AAW22542.1 | Myosin light chain | -1.76 | 1.00E-03 | -2.23 | 3.73E-04 |
| ACO10528.1 | Troponin C, isoform 1 | -1.91 | 1.69E-03 | -2.22 | 5.12E-04 |
| ACO12630.1 | Troponin C, isoform 1 | -1.61 | 3.01E-05 | -1.51 | 5.92E-04 |
| ACO12421.1 | Tropomodulin | -1.51 | 1.17E-04 | -2.37 | 1.01E-03 |
| ACO12794.1 | Troponin C, isoform 1 | -2.07 | 6.14E-05 | -1.60 | 2.85E-03 |
| ACO14751.1 | Troponin C, isoform 1 | -2.12 | 4.94E-05 | -1.56 | 4.18E-03 |
| ACO11818.1 | Torso-like protein precursor | -1.83 | 5.11E-05 | -1.82 | 9.67E-03 |
| ACO11077.1 | Troponin C, isoform 1 | -1.92 | 6.27E-05 | -1.48 | 1.56E-02 |
| | | | | ||
| XP_002407362.1 | Paxillin | -2.79 | 8.32E-07 | -1.48 | 2.28E-03 |
| | | | | ||
| NP_001032719.1 | Sarco/endoplasmic reticulum calcium transporting ATPase | -2.15 | 8.58E-07 | -2.46 | 2.15E-04 |
| | | | | ||
| XP_002734090.1 | Calmodulin-like | -1.60 | 6.41E-05 | -2.46 | 3.25E-04 |
| ACO11757.1 | Sarcoplasmic calcium-binding protein, beta chain | -3.18 | 2.05E-06 | -3.58 | 1.28E-03 |
| | | | | ||
| ADD24515.1 | Cuticle protein 6 | -2.29 | 1.79E-03 | -12.28 | 4.75E-04 |
| ABU41025.1 | Cuticle protein | -2.57 | 2.78E-04 | -12.91 | 1.88E-03 |
| ACO14885.1 | Cuticle protein CP14.6 precursor | -1.77 | 7.50E-04 | -3.40 | 4.67E-03 |
| | | | | ||
| ADD38666.1 | Matrix metalloproteinase-9 | -2.29 | 1.07E-05 | -7.35 | 1.84E-06 |
| ADD38283.1 | Kunitz/BPTI-like toxin | -2.45 | 5.43E-06 | -1.79 | 2.50E-04 |
| ABU41053.1 | Metalloproteinase | -5.61 | 7.00E-06 | -4.38 | 3.99E-04 |
| BAG74353.1 | Metalloproteinase | 14.83 | 8.20E-05 | 18.61 | 4.64E-04 |
| ACO11096.1 | Serine carboxypeptidase CPVL precursor | 1.58 | 2.44E-04 | 1.36 | 1.21E-02 |
| ABU41117.1 | Metalloproteinase | -2.72 | 6.62E-05 | -1.41 | 1.82E-02 |
| AAS91793.1 | Intestinal trypsin 2 precursor | 7.73 | 1.90E-06 | 1.82 | 2.52E-02 |
| AAS91795.1 | Intestinal trypsin 4 precursor | 1.48 | 6.69E-04 | 1.42 | 2.79E-02 |
Annotated genes (57%) were sorted by the significance of differential expression between strains in experiment 1 and arranged by biological function. Features with identical annotation were removed prior to categorising biological function. Also indicated is the percentage representation for each functional category in the total number of annotated genes (129 genes).
Gene expression measured by RT-qPCR in salmon lice from two strains differing in EMB susceptibility
| ADD24187.1 | Neuronal acetylcholine receptor subunit α3 | 7.59E-05 | 0.000 | 0.93 | <0.0001 | 4.29E-03 | 0.009 | 0.89 | 0.0001 | ||||
| EFN73916.1 | GABA receptor subunit alpha | NS | -1.19 | 0.015 | N/A | N/A | 2.05E-04 | 0.005 | 0.89 | 0.0001 | |||
| XP_003494528.1 | Cytochrome p450 18a1 | 3.42E-08 | 0.000 | 0.95 | <0.0001 | N/A | NS | 1.00 | N/A | N/A | |||
| AAS13464.1 | Cytochrome p450 15a1 | 8.93E-04 | 0.000 | 0.95 | <0.0001 | N/A | NS | 1.09 | N/A | N/A | |||
| NP_001136104.1 | Carboxylesterase | 1.13E-04 | 0.041 | 1.21 | 0.65 | 0.02 | NS | 1.12 | NS | 1.12 | N/A | N/A | |
| XP_797271.2 | Maltase-glucoamylase | 9.12E-05 | 0.000 | 0.99 | <0.0001 | 7.10E-03 | 0.017 | ||||||
Abbreviations: NS Not significantly different (p<0.05), N/A Not applicable.
For selected genes, mRNA expression was measured in salmon lice from two strains differing in EMB susceptibility (see Figure 1 for information on strains), results compared to findings obtained in microarray analyses. Significance (p < 0.05) assessed by t-test (Welch) for microarray analysis and one-way ANOVA for RT-qPCR analysis. Fold changes ≥ 1.3 are underlined.
Number of differentially expressed features identified in microarray analysis of samples from experiment 2
| Strain | 5940 (55%) |
| Treatment | 369 (3%) |
| Time | 968 (9%) |
| Strain x Treatment | 406 (4%) |
| Strain x Time | 950 (9%) |
| Time x Treatment | 1309 (12%) |
| Strain x Treatment x Time | 1701 (16%) |
Significance (p-value < 0.05) assessed by three-way ANOVA. Also indicated is the percentage of the total number of features (10, 804) used in the analysis.
Figure 4Gene expression responses at early time points of exposure to EMB. Shown are the relative expression ratios (RER) measured by microarray and RT-qPCR analysis of S and PT salmon louse strains after 1 and 3 hours exposure to 200 μg L-1 EMB, seawater (SW), or the solvent PEG300 (SOL) . Data are Log2 RER ± SE (n = 3).
Figure 5Relative expression profiles for the features in network clusters one (A) and two (B). A total of 418 (cluster 1) and 62 (Cluster 2) features (fold change ≥ 1.3 in S strain) were clustered using network analysis. The similarity of expression profiles were measured using the Pearson correlation coefficient and clustered using the Markov clustering algorithm (MCL).